Get the latest news, insights, and market updates on CAPR (Capricor Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Can Capricor Therapeutics' (CAPR) Exosome Advancement Shift the Conversation on Its Innovation Pipeline?
Capricor Therapeutics recently presented new data at the 2025 American Association for Extracellular Ventures Annual Meeting, highlighting a scalable process for loading therapeutic RNA molecules into exosomes using advanced electroporation techniques. This progress is seen as a significant step for expanding clinical manufacturing capacity, but arrives amid heightened scrutiny following regulatory setbacks and public criticism of the company’s lead therapy for Duchenne muscular dystrophy... Nov 25, 2025 - $CAPR
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamidate morpholino oligomer Nov 24, 2025 - $CAPR
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with Stealth Nov 10, 2025 - $CAPR
Capricor: Q3 Earnings Snapshot
SAN DIEGO (AP) — Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $24.6 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 54 cents. Nov 10, 2025 - $CAPR
CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of +13.95% and +3.65%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $CAPR
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p. Oct 31, 2025 - $CAPR
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Oct 30, 2025 - $CAPR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple